;PMID: 9507564
;source_file_969.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..54] = [t:0..54]
;1)sentence:[e:60..151] = [t:60..151]
;2)section:[e:155..239] = [t:155..239]
;3)section:[e:243..354] = [t:243..354]
;4)sentence:[e:358..615] = [t:358..615]
;5)sentence:[e:616..779] = [t:616..779]
;6)sentence:[e:780..1034] = [t:780..1034]
;7)sentence:[e:1035..1199] = [t:1035..1199]
;8)sentence:[e:1200..1316] = [t:1200..1316]
;9)sentence:[e:1317..1458] = [t:1317..1458]
;10)sentence:[e:1460..1559] = [t:1460..1559]
;11)sentence:[e:1560..1691] = [t:1560..1691]
;12)sentence:[e:1692..1963] = [t:1692..1963]
;13)section:[e:1967..2011] = [t:1967..2011]

;section 0 Span:0..54
;Res Commun Mol Pathol Pharmacol. 1997 Jul;97(1):13-24.
(SEC
  (FRAG (NNP:[0..3] Res) (NNP:[4..10] Commun) (NNP:[11..14] Mol)
        (NNP:[15..21] Pathol) (NNP:[22..31] Pharmacol) (.:[31..32] .)
        (CD:[33..37] 1997) (NNP:[38..45] Jul;97-LRB-) (CD:[45..46] 1)
        (-RRB-:[46..47] -RRB-) (CD:[47..50] :13) (IN:[50..51] -)
        (CD:[51..53] 24) (.:[53..54] .)))

;sentence 1 Span:60..151
;Cyclophosphamide increases 5-hydroxytryptamine release from the isolated
;ileum  of the rat.
;[60..76]:substance:"Cyclophosphamide"
;[87..106]:substance:"5-hydroxytryptamine"
(SENT
  (S-HLN
    (NP-SBJ (NN:[60..76] Cyclophosphamide))
    (VP (VBZ:[77..86] increases)
      (NP
        (NP (NN:[87..106] 5-hydroxytryptamine) (NN:[107..114] release))
        (PP (IN:[115..119] from)
          (NP
            (NP (DT:[120..123] the) (VBN:[124..132] isolated)
                (NN:[133..138] ileum))
            (PP (IN:[140..142] of)
              (NP (DT:[143..146] the) (NN:[147..150] rat)))))))
    (.:[150..151] .)))

;section 2 Span:155..239
;Minami M, Ogawa T, Endo T, Hamaue N, Hirafuji M, Yoshioka M, Blower PR,
;Andrews  PL.
(SEC
  (FRAG (NNP:[155..161] Minami) (VBD:[162..164] M,) (NNP:[165..170] Ogawa)
        (NNP:[171..172] T) (VBD:[172..173] ,) (NNP:[174..178] Endo)
        (NNP:[179..180] T) (,:[180..181] ,) (NNP:[182..188] Hamaue)
        (NNP:[189..190] N) (,:[190..191] ,) (NNP:[192..200] Hirafuji)
        (NNP:[201..203] M,) (NNP:[204..212] Yoshioka) (NNP:[213..215] M,)
        (NNP:[216..222] Blower) (NNP:[223..225] PR) (,:[225..226] ,)
        (NNP:[227..234] Andrews) (NNP:[236..239] PL.)))

;section 3 Span:243..354
;Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health
;Sciences  University of Hokkaido, Japan.
(SEC
  (FRAG (NNP:[243..253] Department) (IN:[254..256] of)
        (NNP:[257..269] Pharmacology) (,:[269..270] ,) (NNP:[271..278] Faculty)
        (IN:[279..281] of) (NNP:[282..296] Pharmaceutical)
        (NNPS:[297..305] Sciences) (,:[305..306] ,) (NNP:[307..313] Health)
        (NNP:[314..322] Sciences) (NNP:[324..334] University) (IN:[335..337] of)
        (NNP:[338..346] Hokkaido) (,:[346..347] ,) (NNP:[348..353] Japan)
        (.:[353..354] .)))

;sentence 4 Span:358..615
;We recently reported that chronic administration of cyclophosphamide 
;significantly increased urinary 5-hydroxyindole acetic acid (5-HIAA)
;excretion  in rats indicative of a release of 5-hydroxytryptamine (5-HT) from
;intestinal  enterochromaffin (EC) cells.
;[410..426]:substance:"cyclophosphamide"
;[460..487]:substance:"5-hydroxyindole acetic acid"
;[489..495]:substance:"5-HIAA"
;[543..562]:substance:"5-hydroxytryptamine"
;[564..568]:substance:"5-HT"
(SENT
  (S
    (NP-SBJ (PRP:[358..360] We))
    (ADVP-TMP (RB:[361..369] recently))
    (VP (VBD:[370..378] reported)
      (SBAR (IN:[379..383] that)
        (S
          (NP-SBJ
            (NP (JJ:[384..391] chronic) (NN:[392..406] administration))
            (PP (IN:[407..409] of)
              (NP (NN:[410..426] cyclophosphamide))))
          (ADVP (RB:[428..441] significantly))
          (VP (VBD:[442..451] increased)
            (NP (JJ:[452..459] urinary)
              (NML
                (NML (NN:[460..475] 5-hydroxyindole) (JJ:[476..482] acetic)
                     (NN:[483..487] acid))
                (NML (-LRB-:[488..489] -LRB-) (NN:[489..495] 5-HIAA)
                     (-RRB-:[495..496] -RRB-)))
              (NN:[497..506] excretion))
            (PP-LOC (IN:[508..510] in)
              (NP (NNS:[511..515] rats)))
            (S-ADV
              (NP-SBJ (-NONE-:[515..515] *))
              (ADJP-PRD (JJ:[516..526] indicative)
                (PP (IN:[527..529] of)
                  (NP
                    (NP (DT:[530..531] a) (NN:[532..539] release))
                    (PP (IN:[540..542] of)
                      (NP
                        (NP (NN:[543..562] 5-hydroxytryptamine))
                        (NP (-LRB-:[563..564] -LRB-) (NN:[564..568] 5-HT)
                            (-RRB-:[568..569] -RRB-))))
                    (PP (IN:[570..574] from)
                      (NP (JJ:[575..585] intestinal)
                        (NML
                          (NML (NN:[587..603] enterochromaffin))
                          (NML (-LRB-:[604..605] -LRB-) (NN:[605..607] EC)
                               (-RRB-:[607..608] -RRB-)))
                        (NNS:[609..614] cells)))))))))))
    (.:[614..615] .)))

;sentence 5 Span:616..779
;Cyclophosphamide is considered to be an inactive  prodrug and require
;conversion to active emetic metabolities (e.g. phosphoramide  mustard) by
;hepatic metabolism.
;[616..632]:substance:"Cyclophosphamide"
;[666..673]:substance:"prodrug"
;[707..726]:substance:"emetic metabolities"
;[733..755]:substance:"phosphoramide  mustard"
(SENT
  (S
    (NP-SBJ-1 (NN:[616..632] Cyclophosphamide))
    (VP (VBZ:[633..635] is)
      (VP (VBN:[636..646] considered)
        (S
          (NP-SBJ-1 (-NONE-:[646..646] *))
          (VP (TO:[647..649] to)
            (VP
              (VP (VB:[650..652] be)
                (NP-PRD (DT:[653..655] an) (JJ:[656..664] inactive)
                        (NN:[666..673] prodrug)))
              (CC:[674..677] and)
              (VP (VB:[678..685] require)
                (NP
                  (NP (NN:[686..696] conversion))
                  (PP (TO:[697..699] to)
                    (NP
                      (NP (JJ:[700..706] active)
                         (JJ:[707..713] emetic) (NNS:[714..726] metabolities))
                      (NP (-LRB-:[727..728] -LRB-)
                        (ADVP (FW:[728..732] e.g.))
                         (NN:[733..746] phosphoramide) (NN:[748..755] mustard)
                        (-RRB-:[755..756] -RRB-))))
                  (PP (IN:[757..759] by)
                    (NP (JJ:[760..767] hepatic) (NN:[768..778] metabolism))))))))))
    (.:[778..779] .)))

;sentence 6 Span:780..1034
;However the presence of cytochrome P450 in the  intestine raises the
;possibility of cyclophosphamide metabolism in the wall of  the intestine, a
;site which would have considerable significance for 5-HT  release and the
;emetic effects of cyclophosphamide.
;[804..819]:cyp450:"cytochrome P450"
;[864..880]:substance:"cyclophosphamide"
;[977..981]:substance:"5-HT"
;[1017..1033]:substance:"cyclophosphamide"
(SENT
  (S
    (ADVP (RB:[780..787] However))
    (NP-SBJ
      (NP (DT:[788..791] the) (NN:[792..800] presence))
      (PP (IN:[801..803] of)
        (NP (NN:[804..814] cytochrome) (NN:[815..819] P450)))
      (PP-LOC (IN:[820..822] in)
        (NP (DT:[823..826] the) (NN:[828..837] intestine))))
    (VP (VBZ:[838..844] raises)
      (NP
        (NP (DT:[845..848] the) (NN:[849..860] possibility))
        (PP (IN:[861..863] of)
          (NP
            (NP (NN:[864..880] cyclophosphamide) (NN:[881..891] metabolism))
            (PP-LOC (IN:[892..894] in)
              (NP
                (NP
                  (NP (DT:[895..898] the) (NN:[899..903] wall))
                  (PP (IN:[904..906] of)
                    (NP (DT:[908..911] the) (NN:[912..921] intestine))))
                (,:[921..922] ,)
                (NP
                  (NP (DT:[923..924] a) (NN:[925..929] site))
                  (SBAR
                    (WHNP-1 (WDT:[930..935] which))
                    (S
                      (NP-SBJ-1 (-NONE-:[935..935] *T*))
                      (VP (MD:[936..941] would)
                        (VP (VB:[942..946] have)
                          (NP (JJ:[947..959] considerable)
                              (NN:[960..972] significance))
                          (PP (IN:[973..976] for)
                            (NP
                              (NP (NN:[977..981] 5-HT) (NN:[983..990] release))
                              (CC:[991..994] and)
                              (NP
                                (NP (DT:[995..998] the) (JJ:[999..1005] emetic)
                                    (NNS:[1006..1013] effects))
                                (PP (IN:[1014..1016] of)
                                  (NP (NN:[1017..1033] cyclophosphamide)))))))))))))))))
    (.:[1033..1034] .)))

;sentence 7 Span:1035..1199
;The aim of this study was to  investigate whether cyclophosphamide could
;induce the release of 5-HT from the  isolated ileum and to examine its
;mechanism of action.
;[1085..1101]:substance:"cyclophosphamide"
;[1130..1134]:substance:"5-HT"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1035..1038] The) (NN:[1039..1042] aim))
      (PP (IN:[1043..1045] of)
        (NP (DT:[1046..1050] this) (NN:[1051..1056] study))))
    (VP (VBD:[1057..1060] was)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[1060..1060] *))
        (VP
          (VP (TO:[1061..1063] to)
            (VP (VB:[1065..1076] investigate)
              (SBAR (IN:[1077..1084] whether)
                (S
                  (NP-SBJ (NN:[1085..1101] cyclophosphamide))
                  (VP (MD:[1102..1107] could)
                    (VP (VB:[1108..1114] induce)
                      (NP
                        (NP (DT:[1115..1118] the) (NN:[1119..1126] release))
                        (PP (IN:[1127..1129] of)
                          (NP (NN:[1130..1134] 5-HT)))
                        (PP (IN:[1135..1139] from)
                          (NP (DT:[1140..1143] the) (VBN:[1145..1153] isolated)
                              (NN:[1154..1159] ileum))))))))))
          (CC:[1160..1163] and)
          (VP (TO:[1164..1166] to)
            (VP (VB:[1167..1174] examine)
              (NP
                (NP (PRP$:[1175..1178] its) (NN:[1179..1188] mechanism))
                (PP (IN:[1189..1191] of)
                  (NP (NN:[1192..1198] action)))))))))
    (.:[1198..1199] .)))

;sentence 8 Span:1200..1316
;Cyclophosphamide (10(-6)M  and 10(-7)M) induced a concentration dependent
;increase of 5-HT from rat  isolated ileum.
;[1200..1216]:substance:"Cyclophosphamide"
;[1218..1224]:quantitative-value:"10(-6)"
;[1224..1225]:quantitative-units:"M"
;[1231..1237]:quantitative-value:"10(-7)"
;[1237..1238]:quantitative-units:"M"
;[1286..1290]:substance:"5-HT"
(SENT
  (S
    (NP-SBJ (NN:[1200..1216] Cyclophosphamide)
      (PRN (-LRB-:[1217..1218] -LRB-)
        (NP (CD:[1218..1224] 10-LRB--6-RRB-) (NN:[1224..1225] M))
        (CC:[1227..1230] and)
        (NP (CD:[1231..1237] 10-LRB--7-RRB-) (NN:[1237..1238] M))
        (-RRB-:[1238..1239] -RRB-)))
    (VP (VBD:[1240..1247] induced)
      (NP
        (NP (DT:[1248..1249] a)
          (ADJP (NN:[1250..1263] concentration) (JJ:[1264..1273] dependent))
          (NN:[1274..1282] increase))
        (PP (IN:[1283..1285] of)
          (NP
            (NP (NN:[1286..1290] 5-HT))
            (PP (IN:[1291..1295] from)
              (NP (NN:[1296..1299] rat) (VBN:[1301..1309] isolated)
                  (NN:[1310..1315] ileum)))))))
    (.:[1315..1316] .)))

;sentence 9 Span:1317..1458
;This cyclophosphamide-induced 5-HT release was significantly  reduced by
;granisetron (10(-6)M and 10(-7)M) or atropine (10(-7)M and 10(-6)M).
;[1322..1338]:substance:"cyclophosphamide"
;[1347..1351]:substance:"5-HT"
;[1390..1401]:substance:"granisetron"
;[1403..1409]:quantitative-value:"10(-6)"
;[1409..1410]:quantitative-units:"M"
;[1415..1421]:quantitative-value:"10(-7)"
;[1421..1422]:quantitative-units:"M"
;[1427..1435]:substance:"atropine"
;[1437..1443]:quantitative-value:"10(-7)"
;[1443..1444]:quantitative-units:"M"
;[1449..1455]:quantitative-value:"10(-6)"
;[1455..1456]:quantitative-units:"M"
(SENT
  (S
    (NP-SBJ-1 (DT:[1317..1321] This)
      (ADJP (NN:[1322..1338] cyclophosphamide) (HYPH:[1338..1339] -)
            (VBN:[1339..1346] induced))
      (NN:[1347..1351] 5-HT) (NN:[1352..1359] release))
    (VP (VBD:[1360..1363] was)
      (ADVP (RB:[1364..1377] significantly))
      (VP (VBN:[1379..1386] reduced)
        (NP-1 (-NONE-:[1386..1386] *))
        (PP (IN:[1387..1389] by)
          (NP-LGS
            (NP (NN:[1390..1401] granisetron)
              (PRN (-LRB-:[1402..1403] -LRB-)
                (NP
                  (NP (CD:[1403..1409] 10-LRB--6-RRB-) (NN:[1409..1410] M))
                  (CC:[1411..1414] and)
                  (NP (CD:[1415..1421] 10-LRB--7-RRB-) (NN:[1421..1422] M)))
                (-RRB-:[1422..1423] -RRB-)))
            (CC:[1424..1426] or)
            (NP (NN:[1427..1435] atropine)
              (PRN (-LRB-:[1436..1437] -LRB-)
                (NP
                  (NP (CD:[1437..1443] 10-LRB--7-RRB-) (NN:[1443..1444] M))
                  (CC:[1445..1448] and)
                  (NP (CD:[1449..1455] 10-LRB--6-RRB-) (NN:[1455..1456] M)))
                (-RRB-:[1456..1457] -RRB-)))))))
    (.:[1457..1458] .)))

;sentence 10 Span:1460..1559
;Tetrodotoxin (10(-6)M completely inhibited the increased 5-HT release induced
;by  cyclophosphamide.
;[1460..1472]:substance:"Tetrodotoxin"
;[1474..1480]:quantitative-value:"10(-6)"
;[1480..1481]:quantitative-units:"M"
;[1517..1521]:substance:"5-HT"
;[1542..1558]:substance:"cyclophosphamide"
(SENT
  (S
    (NP-SBJ (NN:[1460..1472] Tetrodotoxin)
      (PRN (-LRB-:[1473..1474] -LRB-)
        (NP (CD:[1474..1480] 10-LRB--6-RRB-) (NN:[1480..1481] M))))
    (ADVP (RB:[1482..1492] completely))
    (VP (VBD:[1493..1502] inhibited)
      (NP
        (NP (DT:[1503..1506] the) (VBN:[1507..1516] increased)
            (NN:[1517..1521] 5-HT) (NN:[1522..1529] release))
        (VP (VBN:[1530..1537] induced)
          (NP (-NONE-:[1537..1537] *))
          (PP-MNR (IN:[1538..1540] by)
            (NP (NN:[1542..1558] cyclophosphamide))))))
    (.:[1558..1559] .)))

;sentence 11 Span:1560..1691
;These results suggest that cyclophosphamide has the capacity  to induce 5-HT
;release via activation of enteric cholinergic neurons.
;[1587..1603]:substance:"cyclophosphamide"
;[1632..1636]:substance:"5-HT"
(SENT
  (S
    (NP-SBJ (DT:[1560..1565] These) (NNS:[1566..1573] results))
    (VP (VBP:[1574..1581] suggest)
      (SBAR (IN:[1582..1586] that)
        (S
          (NP-SBJ (NN:[1587..1603] cyclophosphamide))
          (VP (VBZ:[1604..1607] has)
            (NP (DT:[1608..1611] the) (NN:[1612..1620] capacity)
              (S
                (NP-SBJ (-NONE-:[1620..1620] *))
                (VP (TO:[1622..1624] to)
                  (VP (VB:[1625..1631] induce)
                    (NP (NN:[1632..1636] 5-HT) (NN:[1637..1644] release))
                    (PP (IN:[1645..1648] via)
                      (NP
                        (NP (NN:[1649..1659] activation))
                        (PP (IN:[1660..1662] of)
                          (NP (JJ:[1663..1670] enteric)
                              (JJ:[1671..1682] cholinergic)
                              (NNS:[1683..1690] neurons)))))))))))))
    (.:[1690..1691] .)))

;sentence 12 Span:1692..1963
;In  addition the in vitro study demonstrate for the first time that
;cyclophosphamide  may be activated to emetic metabolites at extra-hepatic
;sites (e.g. intestine)  and that conversion at these sites could contribute
;to the mechanism of  cyclophosphamide induced emesis.
;[1760..1776]:substance:"cyclophosphamide"
;[1798..1816]:substance:"emetic metabolites"
;[1931..1947]:substance:"cyclophosphamide"
(SENT
  (S
    (PP (IN:[1692..1694] In)
      (NP (NN:[1696..1704] addition)))
    (NP-SBJ (DT:[1705..1708] the)
      (ADJP (FW:[1709..1711] in) (FW:[1712..1717] vitro))
      (NN:[1718..1723] study))
    (VP (VBP:[1724..1735] demonstrate)
      (PP (IN:[1736..1739] for)
        (NP (DT:[1740..1743] the) (JJ:[1744..1749] first) (NN:[1750..1754] time)))
      (SBAR
        (SBAR (IN:[1755..1759] that)
          (S
            (NP-SBJ-1 (NN:[1760..1776] cyclophosphamide))
            (VP (MD:[1778..1781] may)
              (VP (VB:[1782..1784] be)
                (VP (VBN:[1785..1794] activated)
                  (NP-1 (-NONE-:[1794..1794] *))
                  (PP (TO:[1795..1797] to)
                    (NP (JJ:[1798..1804] emetic) (NNS:[1805..1816] metabolites)))
                  (PP-LOC (IN:[1817..1819] at)
                    (NP
                      (ADJP (AFX:[1820..1825] extra) (HYPH:[1825..1826] -)
                            (JJ:[1826..1833] hepatic))
                      (NNS:[1834..1839] sites)
                      (PRN (-LRB-:[1840..1841] -LRB-)
                        (NP
                          (ADVP (FW:[1841..1845] e.g.))
                          (NN:[1846..1855] intestine))
                        (-RRB-:[1855..1856] -RRB-)))))))))
        (CC:[1858..1861] and)
        (SBAR (IN:[1862..1866] that)
          (S
            (NP-SBJ
              (NP (NN:[1867..1877] conversion))
              (PP-LOC (IN:[1878..1880] at)
                (NP (DT:[1881..1886] these) (NNS:[1887..1892] sites))))
            (VP (MD:[1893..1898] could)
              (VP (VB:[1899..1909] contribute)
                (PP-CLR (TO:[1910..1912] to)
                  (NP
                    (NP (DT:[1913..1916] the) (NN:[1917..1926] mechanism))
                    (PP (IN:[1927..1929] of)
                      (NP
                        (ADJP (NN:[1931..1947] cyclophosphamide)
                              (VBN:[1948..1955] induced))
                        (NN:[1956..1962] emesis)))))))))))
    (.:[1962..1963] .)))

;section 13 Span:1967..2011
;PMID: 9507564 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1967..1971] PMID) (::[1971..1972] :) (CD:[1973..1980] 9507564)
        (IN:[1981..1982] -LSB-) (NNP:[1982..1988] PubMed) (HYPH:[1989..1990] -)
        (JJ:[1991..1998] indexed) (IN:[1999..2002] for)
        (NNP:[2003..2011] MEDLINE-RSB-)))
